CN Patent

CN102725283B — 作为蛋白激酶抑制剂的化合物和组合物

Assigned to Alec Biopharmaceutical Co · Expires 2014-02-26 · 12y expired

What this patent protects

本发明提供了一类新的式I化合物、含有此类化合物的药物组合物以及采用此类化合物治疗或预防疾病或障碍的方法，所述疾病或障碍与激酶活性异常或失控有关，尤其是涉及B-Raf异常激活的疾病或障碍。

USPTO Abstract

本发明提供了一类新的式I化合物、含有此类化合物的药物组合物以及采用此类化合物治疗或预防疾病或障碍的方法，所述疾病或障碍与激酶活性异常或失控有关，尤其是涉及B-Raf异常激活的疾病或障碍。

Drugs covered by this patent

Patent Metadata

Patent number
CN102725283B
Jurisdiction
CN
Classification
—
Expires
2014-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Alec Biopharmaceutical Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.